STOCK TITAN

Somalogic, Inc. - SLGC STOCK NEWS

Welcome to our dedicated page for Somalogic news (Ticker: SLGC), a resource for investors and traders seeking the latest updates and insights on Somalogic stock.

SomaLogic, Inc. (Nasdaq: SLGC) delivers cutting-edge proteomics solutions to advance disease research and diagnostic capabilities. This dedicated news center provides stakeholders with timely updates on strategic developments, financial milestones, and technological breakthroughs shaping the future of healthcare innovation.

Investors and industry professionals will find authoritative coverage of SLGC's proposed merger with Standard BioTools, quarterly earnings reports, and collaborations driving precision medicine. Our repository includes verified press releases on platform enhancements, clinical study outcomes, and executive leadership decisions.

Key focus areas span oncology, metabolic disease research, and large-scale proteomic data applications. Bookmark this page for streamlined access to SomaLogic's latest regulatory filings, partnership announcements, and peer-reviewed scientific achievements. Visit regularly to stay informed about developments impacting the diagnostics and life sciences sectors.

Rhea-AI Summary
SomaLogic, Inc. will report financial results for Q3 2023 on November 8, 2023, after market close. A conference call will be hosted by management at 4:30 p.m. Eastern Time. Interested participants can register online and access the webcast at https://investors.somalogic.com/.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.35%
Tags
-
Rhea-AI Summary
OncoHost has developed a computational model to predict immune-related adverse events (irAEs) in NSCLC patients based on proteomic profiling of pre-treatment blood samples. The study will be presented at the SITC Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.21%
Tags
conferences
-
Rhea-AI Summary
OncoHost's peer-reviewed study demonstrates the strong analytical capabilities of its PROphet test for personalized treatment guidance in metastatic NSCLC patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.78%
Tags
none
Rhea-AI Summary
Lifshitz Law PLLC announces investigations of SLGC, ORTX, SP
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.85%
Tags
none
-
Rhea-AI Summary
OncoHost collaborates with Henlius USA to identify biomarkers in a Phase III clinical trial for Extensive-Stage Small Cell Lung Cancer. OncoHost's PROphet® platform combines bioinformatics, proteomic pattern recognition, and machine learning to predict clinical benefit probability. The collaboration aims to improve personalized care and bring new hope to cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
-
Rhea-AI Summary
SomaLogic partners with DNA Link to offer the 7,000-plex SomaScan platform in Korea, expanding DNA Link's proteomics capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
partnership
Rhea-AI Summary
SomaLogic's research identifies 15 blood proteins shared among all cancer types and models to stratify tumor types, potentially improving early detection of cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.28%
Tags
none
-
Rhea-AI Summary
Novo Nordisk extends collaborative agreement with SomaLogic, expanding use of proteomics platform in drug research and development, and investigations into cardiometabolic and other diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.98%
Tags
none
-
Rhea-AI Summary
SomaLogic reports Q2 2023 revenue of $20.5M, a 45% YoY increase. Cash and investments at $474M. Reiterates full year 2023 revenue guidance of $80-84M. Net loss of $24.8M. Lower R&D and SG&A expenses. Adjusted EBITDA loss of $28.9M. Strong financial position.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.4%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
Somalogic, Inc.

Nasdaq:SLGC

SLGC Rankings

SLGC Stock Data

396.23M
175.53M
2.16%
61.71%
3.79%
Health Information Services
Healthcare
Link
United States
Boulder